FDA has approved a new drug Lartruvo for soft tissue sarcoma. This drugs contains active ingredient olaratumab which monoclonal antibody and extracted from human origin.Monoclonal antibodies are derived from cells of immune system and have high affinity for binding to specific site. Monoclonal antibodies are commonly usedin chemotherapy to target specific site and minimize the chances of toxicity.
FDA recommended the usage of newly approved drug Lartruvo (olaratumab) in combination with doxorubicin to make soft tissue sarcoma treatment more effective.According to guidelines provided by FDA this drug along with doxorubicin should only be used in those patients who are not recovering after radiation or surgery.
Soft tissue sarcoma (STC) is a kind of tumor that originates from connective tissues. There are number of underlying factors that contribute towards development of soft tissue sarcoma. For example excessive exposure to toxic substances in chemical industries, severe viral infection, genetic predisposition, environmental exposure or pollution etc.
Basic mechanism of Lartruvo (olaratumab) is that it blocks platelet derived growth factor (PDGF) receptor alpha that increases the growth of soft tissue sarcoma. PDGF is basically a protein that contributes in tumor growth. Latruvo decreases the progression of this disease by blocking these proteins.
Lartruvo/olaratumab Side effectsAccording to data received from clinical trails following side effects were observed initially,
- Neuropathy or Nerve damage
- Loss of appetite
- Low white blood cells count (Neutropenia)
- Fetal abnormalities
- Reactions during infusion
- Blood pressure fluctuations
- Swelling of mucous membranes
- Musculoskeletal pain
- Abdominal discomfort
Lartruvo/olaratumab prescribing information/usesAccording to data provided by U.S FDA this drug is reserved for those patients who are not responding to radiations or surgery. FDA also recommended that this drug should be used in combination with doxorubicin to make the treatment more targeted and effective.
Lartruvo/olaratumab DosageThis drug is formulated as a 50ml vial for intravenous use with potency of 10mg/ml. Standard dosage of lartruvo for the treatment of soft tissue sarcoma is 15mg/Kg intravenously at rate of 1-8hrs.Dose adjustment can be done depending upon the patient condition and disease progression.
Lartruvo/olaratumab Cost/PriceThis drug is administered by your healthcare practitioner (HCP), which usually means:
- It may comes under special items category.
- You cannot fill this prescription in a regular pharmacy. Your doctor, hospital, or clinic will provide this medication because of possible complications or other issues.
- This drug is likely to be covered under your medical benefit if you have insurance.